These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 27396951)
1. A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. Hayes J; Thygesen H; Gregory W; Westhead DR; French PJ; Van Den Bent MJ; Lawler SE; Short SC Mol Oncol; 2016 Oct; 10(8):1296-304. PubMed ID: 27396951 [TBL] [Abstract][Full Text] [Related]
2. Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Hayes J; Thygesen H; Tumilson C; Droop A; Boissinot M; Hughes TA; Westhead D; Alder JE; Shaw L; Short SC; Lawler SE Mol Oncol; 2015 Mar; 9(3):704-14. PubMed ID: 25499534 [TBL] [Abstract][Full Text] [Related]
3. Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. Erdem-Eraslan L; van den Bent MJ; Hoogstrate Y; Naz-Khan H; Stubbs A; van der Spek P; Böttcher R; Gao Y; de Wit M; Taal W; Oosterkamp HM; Walenkamp A; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; van der Holt B; Vernhout RM; Sillevis Smitt PA; Kros JM; French PJ Cancer Res; 2016 Feb; 76(3):525-34. PubMed ID: 26762204 [TBL] [Abstract][Full Text] [Related]
4. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478 [TBL] [Abstract][Full Text] [Related]
11. Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma. Choi SW; Shin H; Sa JK; Cho HJ; Koo H; Kong DS; Seol HJ; Nam DH Cancer Med; 2018 May; 7(5):1774-1783. PubMed ID: 29573206 [TBL] [Abstract][Full Text] [Related]
12. The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial. Weller J; Zeyen T; Schäfer N; Schaub C; Potthoff AL; Steinbach JP; Hau P; Seidel C; Goldbrunner R; Tabatabai G; Vatter H; Tzaridis T; Schneider M; Herrlinger U J Neurooncol; 2023 Sep; 164(3):749-755. PubMed ID: 37787906 [TBL] [Abstract][Full Text] [Related]
13. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507 [TBL] [Abstract][Full Text] [Related]
14. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933 [TBL] [Abstract][Full Text] [Related]
16. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy. Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114 [TBL] [Abstract][Full Text] [Related]
17. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718 [TBL] [Abstract][Full Text] [Related]
18. Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. Bronnimann C; Izquierdo C; Cartalat S; Thomas L; Joubert B; Delpech L; Barritault M; Meyronet D; Honnorat J; Ducray F J Neurooncol; 2018 May; 138(1):141-145. PubMed ID: 29388033 [TBL] [Abstract][Full Text] [Related]
19. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518 [TBL] [Abstract][Full Text] [Related]
20. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]